Protocol Ledger

NCT03981744 · Phase III · TERMINATED

A Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care Treatments

Interventional Phase III clinical trial protocol NCT03981744 sponsored by Johnson & Johnson / Janssen in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-07-26 Enrollment: 51 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03981744
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)51 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03981744
Protocol FieldVerified Registry Value
NCT IdentifierNCT03981744
Consolidated Lead SponsorJohnson & Johnson / Janssen
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment51 participants (ACTUAL)
Registered Start Date2019-07-26
WhyStopped ClassificationLack of Efficacy / Futility

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03981744
Hospital Research SiteLocationSite Profile
Fukushima Medical University HospitalFukushima, JapanOpen Hospital Dossier ->
Kagoshima University HospitalKagoshima, JapanOpen Hospital Dossier ->
Kumamoto University HospitalKumamoto, JapanOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI